MCID: DBT005
MIFTS: 55

Diabetes Insipidus

Categories: Endocrine diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Diabetes Insipidus

MalaCards integrated aliases for Diabetes Insipidus:

Name: Diabetes Insipidus 12 77 30 6 44 45 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:9409
ICD9CM 36 253.5
MeSH 45 D003919
NCIt 51 C43263
SNOMED-CT 69 15771004
ICD10 34 E23.2
UMLS 74 C0011848

Summaries for Diabetes Insipidus

MedlinePlus : 44 Diabetes insipidus (DI) causes frequent urination. You become extremely thirsty, so you drink. Then you urinate. This cycle can keep you from sleeping or even make you wet the bed. Your body produces lots of urine that is almost all water. DI is different from diabetes mellitus (DM), which involves insulin problems and high blood sugar. The symptoms can be similar. However, DI is related to how your kidneys handle fluids. It's much less common than DM. Urine and blood tests can show which one you have. Usually, DI is caused by a problem with your pituitary gland or your kidneys. Treatment depends on the cause of the problem. Medicines can often help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Insipidus is related to diabetes insipidus, nephrogenic, x-linked and diabetes insipidus, nephrogenic, autosomal. An important gene associated with Diabetes Insipidus is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Neuroscience and Glucose / Energy Metabolism. The drugs Tolvaptan and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include pituitary, heart and kidney, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 77 Diabetes insipidus (DI) is a condition characterized by large amounts of dilute urine and increased... more...

Related Diseases for Diabetes Insipidus

Diseases in the Diabetes Insipidus family:

Hereditary Central Diabetes Insipidus Acquired Central Diabetes Insipidus

Diseases related to Diabetes Insipidus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 485)
# Related Disease Score Top Affiliating Genes
1 diabetes insipidus, nephrogenic, x-linked 34.8 AQP2 AVPR2
2 diabetes insipidus, nephrogenic, autosomal 34.2 AQP2 ARHGAP4 AVP AVPR2 CLCNKA SLC12A1
3 diabetes insipidus, neurohypophyseal 33.8 AQP2 AVP AVPR2 POMC PRL
4 wolfram syndrome 1 33.8 AVP WFS1
5 wolfram syndrome 33.7 AVP CISD2 WFS1
6 wolfram syndrome 2 32.4 CISD2 WFS1
7 bronchus cancer 30.6 AVP POMC
8 pituitary hormone deficiency, combined, 2 30.4 AVP POMC PRL
9 syndrome of inappropriate antidiuretic hormone 30.3 AQP2 AVP AVPR2 POMC
10 nephrogenic syndrome of inappropriate antidiuresis 30.3 AVP AVPR2
11 burns 30.1 CRH INS
12 bartter disease 30.0 CLCNKA REN SLC12A1
13 empty sella syndrome 30.0 POMC PRL
14 lung oat cell carcinoma 29.9 AVP POMC
15 hypoadrenalism 29.9 CRH POMC
16 familial glucocorticoid deficiency 29.9 POMC REN
17 polycystic kidney disease 29.9 AQP2 AVPR2 REN
18 idiopathic edema 29.9 AQP2 INS
19 pituitary apoplexy 29.9 INS POMC PRL
20 hypopituitarism 29.8 CRH INS POMC PRL
21 hypoaldosteronism 29.8 POMC REN
22 amenorrhea 29.7 CRH POMC PRL
23 liver cirrhosis 29.7 AQP2 AVP REN
24 acromegaly 29.6 INS POMC PRL
25 inappropriate adh syndrome 29.5 AQP2 AVP AVPR2 POMC REN
26 pituitary infarct 29.5 POMC PRL
27 adenohypophysitis 29.5 POMC PRL
28 hypokalemia 29.5 AQP2 POMC REN SLC12A1
29 anorexia nervosa 29.2 CRH POMC PRL
30 conn's syndrome 29.1 CRH POMC PRL REN
31 chromophobe adenoma 29.1 AVP INS POMC PRL
32 sheehan syndrome 29.0 CRH INS POMC PRL
33 pituitary gland disease 28.6 AVP CRH INS POMC PRL
34 diabetes insipidus, nephrogenic, with mental retardation and intracerebral calcification 12.5
35 hereditary central diabetes insipidus 12.5
36 acquired central diabetes insipidus 12.5
37 gestational diabetes insipidus 12.4
38 dipsogenic diabetes insipidus 12.4
39 hypopituitarism, congenital, with central diabetes insipidus 12.2
40 x-linked intellectual disability-limb spasticity-retinal dystrophy-diabetes insipidus syndrome 12.2
41 langerhans cell histiocytosis 11.6
42 erdheim-chester disease 11.5
43 wolfram syndrome, mitochondrial form 11.2
44 hyperostosis frontalis interna 11.2
45 polyhydramnios, megalencephaly, and symptomatic epilepsy 11.2
46 wolfram-like syndrome, autosomal dominant 11.2
47 culler-jones syndrome 11.2
48 hashimoto-pritzker syndrome 11.2
49 diabetes mellitus 10.7
50 histiocytosis 10.7

Comorbidity relations with Diabetes Insipidus via Phenotypic Disease Network (PDN):


Acute Cystitis Diabetes Insipidus, Nephrogenic, Autosomal
Hypothyroidism Pituitary Hormone Deficiency, Combined, 2

Graphical network of the top 20 diseases related to Diabetes Insipidus:



Diseases related to Diabetes Insipidus

Symptoms & Phenotypes for Diabetes Insipidus

MGI Mouse Phenotypes related to Diabetes Insipidus:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 AQP2 AVP AVPR2 CISD2 CRH INS
2 homeostasis/metabolism MP:0005376 10.03 AQP2 AVP AVPR2 CISD2 CLCNKA CRH
3 growth/size/body region MP:0005378 10.02 AQP2 AVPR2 CISD2 CLCNKA CRH INS
4 integument MP:0010771 9.81 AQP2 AVPR2 CISD2 CRH INS POMC
5 mortality/aging MP:0010768 9.65 AQP2 AVP AVPR2 CISD2 CLCNKA INS
6 renal/urinary system MP:0005367 9.32 AQP2 AVP AVPR2 CISD2 CLCNKA CRH

Drugs & Therapeutics for Diabetes Insipidus

Drugs for Diabetes Insipidus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 382)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tolvaptan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150683-30-0 216237
2
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-03-3
3
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-23-7 5754
4
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
5
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
6
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
7
Conivaptan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 210101-16-9 151171
8
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-41-2 439260
9
Furosemide Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54-31-9 3440
10
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 2078-54-8 4943
11
Sevoflurane Approved, Vet_approved Phase 4,Phase 1,Not Applicable 28523-86-6 5206
12
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
13
Misoprostol Approved Phase 4,Phase 2,Phase 3 59122-46-2 5282381
14
Phenylephrine Approved Phase 4,Phase 2,Not Applicable 59-42-7 6041
15
Oxymetazoline Approved, Investigational Phase 4,Phase 2,Not Applicable 1491-59-4 4636
16
Pseudoephedrine Approved Phase 4,Phase 2,Not Applicable 90-82-4 7028
17
Ephedrine Approved Phase 4,Phase 2,Not Applicable 299-42-3 9294
18
Metolazone Approved Phase 4,Phase 1 17560-51-9 4170
19
Liraglutide Approved Phase 4 204656-20-2 44147092
20
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
21
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
22
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
23
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
24
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
25
tannic acid Approved Phase 4,Phase 2,Not Applicable 1401-55-4
26
Benzocaine Approved, Investigational Phase 4,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
27
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2 2920-86-7
28
Synephrine Experimental Phase 4 1994-07-5, 94-07-5 7172
29 Vasopressins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Coagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Hemostatics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Natriuretic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 arginine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Arginine Vasopressin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Deamino Arginine Vasopressin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antidiuretic Hormone Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Hydrocortisone hemisuccinate Phase 4,Phase 2,Phase 3
43 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 1
44 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Anesthetics Phase 4,Phase 3,Phase 1,Not Applicable
46 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Hypnotics and Sedatives Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 481)
# Name Status NCT ID Phase Drugs
1 Desmopressin for Improving Nocturnal Enuresis in Patients After Radical Cystectomy With Bladder Reconstruction Unknown status NCT01582542 Phase 4 Desmopressin
2 Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study Unknown status NCT01439997 Phase 4 Desmopressin
3 Desmopressin for Bleeding Related to Low Body Temperature Unknown status NCT00902057 Phase 4 desmopressin;desmopressin;desmopressin;placebo
4 Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
5 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
6 Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites Unknown status NCT01552590 Phase 4 Tolvaptan;Placebo
7 Pilot Study of Using Copeptin to Predict Response to Tolvaptan Completed NCT01346072 Phase 4 tolvaptan
8 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy Completed NCT00748072 Phase 4 DDAVP;saline solution
9 The Effect of Midazolam Premedication on Copeptine Concentration in Blood Completed NCT03474939 Phase 4 Midazolam Oral Tablet
10 Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest Completed NCT00127907 Phase 4 epinephrine (1 mg/1 mL);arginine-vasopressin (40 UI/2 mL)
11 Desmopressin in Cardiac Surgery Completed NCT00337766 Phase 4 Desmopressin (DDAVP);Placebo
12 Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity Completed NCT00902655 Phase 4 Desmopressin
13 Study of the Use of Misoprostol to Decrease Bleeding During a Myomectomy Completed NCT01700478 Phase 4 Misoprostol + vasopressin;Vasopressin
14 Desmopressin Melt: Impact on Sleep and Daytime Functioning Completed NCT01645475 Phase 4 Desmopressin lyophilisate (Melt)
15 Effects of Tolvaptan in Healthy Adults Completed NCT01973140 Phase 4 Tolvaptan;Hypertonic saline infusion
16 Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients Completed NCT01752543 Phase 4 Conivaptan;Placebo (Dextrose)
17 A New Check-list Method for Nocturnal Enuresis Completed NCT03510975 Phase 4 desmopressin melt form 120 μg
18 Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population Completed NCT02584231 Phase 4 desmopressin
19 Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery Completed NCT02125188 Phase 4 Desmopressin;saline
20 Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery Completed NCT01994330 Phase 4 desmopressin
21 Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study Completed NCT01435083 Phase 4 Desmopressin
22 Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation Completed NCT01036841 Phase 4 desmopressin tablet;desmopressin MELT formulation
23 A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis Completed NCT00245479 Phase 4 Primary nocturnal enuresis
24 A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE) Completed NCT00209261 Phase 4 MINIRIN Oral Lyophilisate;Minirin tablet
25 Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial Completed NCT01393704 Phase 4 Vasopressin
26 Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial Completed NCT00799292 Phase 4 Vasopressin
27 Effects of Vasopressors on Immune Response Completed NCT02675868 Phase 4 Norepinephrine;Phenylephrine;Vasopressins;Placebo
28 Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients Completed NCT01439009 Phase 4 Tolvaptan;Placebo of tolvaptan
29 Tolvaptan for Ascites in Cirrhotic Patients Completed NCT01292304 Phase 4 Tolvaptan
30 Tolvaptan in Hyponatremic Cancer Patients Completed NCT01199198 Phase 4 Tolvaptan;Placebo
31 A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia Completed NCT00435591 Phase 4 Conivaptan;placebo
32 Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure Completed NCT01863511 Phase 4 loop diuretic;tolvaptan
33 Aquaresis Utility for Hyponatremic Acute Heart Failure Study Completed NCT02183792 Phase 4 Tolvaptan;Furosemide
34 LIPT - Liraglutide in Polycystic Ovary Syndrome Completed NCT02073929 Phase 4 Liraglutide for 26 weeks;placebo
35 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4 tolvaptan+torasemide;placebo+torasemide
36 Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure Completed NCT02606253 Phase 4 tolvaptan;Chlorothiazide;Metolazone
37 Metabolism of Isotonic Versus Hypotonic Maintenance Solutions in Fasting Healthy Adults Completed NCT02822898 Phase 4 NaCl 0.9% in Glucose 5% with 40mEq Potassium;Glucion 5%
38 Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders Recruiting NCT02476409 Phase 4 tolvaptan
39 The Effect of Selecting Treatment With Desmopressin or Alarm to Children With Enuresis Based on Home Recordings. Recruiting NCT03389412 Phase 4 Desmopressin
40 Effect of Supplemental Oxygen on Perioperative BNP Concentration in Cardiac Risk Patients Recruiting NCT03366857 Phase 4 Oxygen 30 %;Oxygen 80 %
41 The Effect of Propofol or Sevoflurane on Renal Function Recruiting NCT03336801 Phase 4 Propofol;Sevoflurane
42 Exercise Versus DDAVP in Patients With Mild Hemophilia A Recruiting NCT03379974 Phase 4 DDAVP Inhalant Product
43 DDAVP vs. Exercise in Patients With Mild Hemophilia A Recruiting NCT03136003 Phase 4 DDAVP
44 Combined Vaginal Misoprostol and Perivascular Vasopressin Recruiting NCT03815344 Phase 4 Standard;Standard-vaginal misoprostol
45 Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease Recruiting NCT03596957 Phase 4 Tolvaptan
46 Regional Tolvaptan Registry Recruiting NCT02666651 Phase 4 Tolvaptan
47 Tolvaptan for Advanced or Refractory Heart Failure Recruiting NCT02959411 Phase 4 Tolvaptan;Standard of care diuretic therapy
48 Effect of Vasopressin, Steroid, and Epinephrine Treatment in Patients With Out-of-hospital Cardiac Arrest Recruiting NCT03317197 Phase 4 Control Group;Experimental Group 1;Experimental Group 2;Experimental Group 3
49 Vasoactive Drugs in Intensive Care Unit Recruiting NCT02118467 Phase 4 Norepinephrine;Epinephrine;Phenylephrine;Vasopressin
50 Effects of Prophylactic Desmopressin on Blood Coagulation Parameters in Heart Valve Surgery Active, not recruiting NCT03343418 Phase 4 Desmopressin;Placebo

Search NIH Clinical Center for Diabetes Insipidus

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: diabetes insipidus

Genetic Tests for Diabetes Insipidus

Genetic tests related to Diabetes Insipidus:

# Genetic test Affiliating Genes
1 Diabetes Insipidus 30

Anatomical Context for Diabetes Insipidus

MalaCards organs/tissues related to Diabetes Insipidus:

42
Pituitary, Heart, Kidney, Brain, Liver, Testes, Lung

Publications for Diabetes Insipidus

Articles related to Diabetes Insipidus:

(show top 50) (show all 3049)
# Title Authors Year
1
Central diabetes insipidus associated with refeeding in anorexia nervosa: A case report. ( 31038775 )
2019
2
Severe congenital nephrogenic diabetes insipidus in a compound heterozygote with a new large deletion of the AQP2 gene. A case report. ( 30784238 )
2019
3
Diabetes Insipidus and Syndrome of Inappropriate Antidiuretic Hormone in Critically Ill Patients. ( 30784603 )
2019
4
Truncating RAX mutations: anophthalmia, hypopituitarism, diabetes insipidus and cleft palate in mice and men. ( 30811539 )
2019
5
Diabetes insipidus. ( 30819684 )
2019
6
Generalized eruptive histiocytoma developing into xanthoma disseminatum with central diabetes insipidus. ( 30859591 )
2019
7
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and Subsequent Central Diabetes Insipidus: A Rare Presentation of Pituitary Apoplexy. ( 31061738 )
2019
8
Renal Tubular Acidosis Presenting as Nephrogenic Diabetes Insipidus. ( 31064905 )
2019
9
Intense Pituitary 18F-FDG Uptake of Patients with Diabetes Insipidus ( 31070343 )
2019
10
Diabetes insipidus-an extremely rare complication from replacement of an external ventricular drain. ( 31073783 )
2019
11
Langerhans' cell histiocytosis of the temporal bone in an adult with central diabetes insipidus. ( 31080537 )
2019
12
Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis: Results from the JLSG-96/02 studies. ( 30207064 )
2019
13
Genetic deletion of ADP-activated P2Y12 receptor ameliorates lithium-induced nephrogenic diabetes insipidus in mice. ( 30257062 )
2019
14
Diagnosis and management of central diabetes insipidus in adults. ( 30269342 )
2019
15
Nephrogenic Diabetes Insipidus. ( 30454745 )
2019
16
Central diabetes insipidus: A rare complication of IVH in a very low birth weight preterm infant. ( 30530977 )
2019
17
Endoplasmic reticulum stress induces apoptosis of arginine vasopressin neurons in central diabetes insipidus via PI3K/Akt pathway. ( 30677238 )
2019
18
Acute myeloid leukemia with central diabetes insipidus. ( 30709625 )
2019
19
Renal response to an oral protein load in patients with central diabetes insipidus before and after treatment with vasopressin. ( 30778919 )
2019
20
Hyperemesis gravidarum followed by refeeding syndrome causes electrolyte abnormalities induced rhabdomyolysis and diabetes insipidus. ( 30700639 )
2019
21
Trametinib Toxicities in Patients With Low-grade Gliomas and Diabetes Insipidus: Related Findings? ( 30676433 )
2019
22
Gestational diabetes insipidus. ( 30371855 )
2019
23
Complete Nephrogenic Diabetes Insipidus After Prolonged Sevoflurane Sedation: A Case Report of 3 Cases. ( 30130280 )
2019
24
A novel mechanism of autophagy-associated cell death of vasopressin neurons in familial neurohypophysial diabetes insipidus. ( 29961215 )
2019
25
Relation between change in treatment for central diabetes insipidus and body weight loss. ( 29424204 )
2019
26
Partial nephrogenic diabetes insipidus associated with Castleman's disease. ( 31088379 )
2019
27
Central diabetes insipidus emerging after steroid replacement in pituitary apoplexy. ( 31061075 )
2019
28
Causes and Follow-Up of Central Diabetes Insipidus in Children. ( 31049061 )
2019
29
A novel AVPR2 missense mutation in an Asian family with inherited nephrogenic diabetes insipidus: A case report. ( 31027113 )
2019
30
Daily Sodium Monitoring and Fluid Intake Protocol: Preventing Recurrent Hospitalization in Adipsic Diabetes Insipidus. ( 31008421 )
2019
31
Lithium treatment, nephrogenic diabetes insipidus and the risk of hypernatraemia: a retrospective cohort study. ( 31007893 )
2019
32
Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis (SIAD). ( 31004513 )
2019
33
Long-term outcome in inherited nephrogenic diabetes insipidus. ( 30976394 )
2019
34
Hydranencephaly complicated by central diabetes insipidus: report of two cases and systematic review of literature. ( 30929071 )
2019
35
Nephrogenic diabetes insipidus after esophagectomy in a patient with remote history of lithium treatment: A case report. ( 30921589 )
2019
36
Nephrogenic diabetes insipidus associated with prolonged sedation with sevoflurane in the intensive care unit. ( 30916031 )
2019
37
A Case Report of Diabetes Insipidus After Renal Transplant. ( 30885068 )
2019
38
Low Plasma Oxytocin Levels and Increased Psychopathology in Hypopituitary Men with Diabetes Insipidus. ( 30882859 )
2019
39
Adipsic diabetes insipidus secondary to craniopharyngioma resection. ( 30709829 )
2019
40
A novel missense mutation in TFAP2B associated with Char syndrome and central diabetes insipidus. ( 31012281 )
2019
41
The Relationship Between Posterior Pituitary Bright Spot on Magnetic Resonance Imaging (MRI) and Postoperative Diabetes Insipidus for Pituitary Adenoma Patients. ( 30228254 )
2018
42
Hypopituitarism and Central Diabetes Insipidus Caused by Central Nervous System Lymphoma. ( 29984760 )
2018
43
Incidence of pituitary autoantibodies in idiopathic diabetes insipidus. ( 30799991 )
2018
44
Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus. ( 29081004 )
2018
45
Functional characterization of AVPR2 mutants found in Turkish patients with nephrogenic diabetes insipidus. ( 29117938 )
2018
46
Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis. ( 29141992 )
2018
47
Treatment regimens by pediatric nephrologists in children with congenital nephrogenic diabetes insipidus: A MWPNC study
. ( 29162216 )
2018
48
Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. ( 29220526 )
2018
49
Delayed Occurrence of Diabetes Insipidus After Transsphenoidal Surgery with Radiologic Evaluation of the Pituitary Stalk on Magnetic Resonance Imaging. ( 29229338 )
2018
50
Rapid differential diagnosis of diabetes insipidus in a 7-month-old infant: The copeptin approach. ( 29241593 )
2018

Variations for Diabetes Insipidus

ClinVar genetic disease variations for Diabetes Insipidus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MATN4 NM_030590.3(MATN4): c.515G> C (p.Gly172Ala) single nucleotide variant Likely pathogenic rs730882210 GRCh38 Chromosome 20, 45304356: 45304356
2 MATN4 NM_030590.3(MATN4): c.515G> C (p.Gly172Ala) single nucleotide variant Likely pathogenic rs730882210 GRCh37 Chromosome 20, 43932996: 43932996

Expression for Diabetes Insipidus

Search GEO for disease gene expression data for Diabetes Insipidus.

Pathways for Diabetes Insipidus

GO Terms for Diabetes Insipidus

Cellular components related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 AVP CRH INS POMC PRL REN
2 endosome lumen GO:0031904 8.96 INS PRL
3 secretory granule GO:0030141 8.62 AVP POMC

Biological processes related to Diabetes Insipidus according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.78 AVP INS POMC PRL
2 positive regulation of gene expression GO:0010628 9.76 AVP AVPR2 CRH INS
3 positive regulation of cell proliferation GO:0008284 9.55 AVP AVPR2 CRH INS PRL
4 glucose homeostasis GO:0042593 9.54 INS POMC WFS1
5 positive regulation of vasoconstriction GO:0045907 9.51 AVP AVPR2
6 response to immobilization stress GO:0035902 9.49 CRH REN
7 water transport GO:0006833 9.43 AQP2 AVP
8 response to ethanol GO:0045471 9.4 AVP CRH
9 positive regulation of systemic arterial blood pressure GO:0003084 9.26 AVP AVPR2
10 excretion GO:0007588 9.13 AQP2 AVPR2 CLCNKA
11 parturition GO:0007567 9.02 CRH
12 renal water homeostasis GO:0003091 8.92 AQP2 AVP AVPR2 WFS1

Molecular functions related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.46 AVP CRH POMC REN
2 neuropeptide hormone activity GO:0005184 9.26 AVP CRH
3 hormone activity GO:0005179 9.02 AVP CRH INS POMC PRL
4 insulin-like growth factor receptor binding GO:0005159 8.96 INS REN

Sources for Diabetes Insipidus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....